Physician profile
Greda Cherry
NPI 1295121697
$637.52
in general payments reported to CMS, 2019-2025
11 companies · $288 in 2025
The $288 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $110 · 2023: $32.70 · 2024: $207 · 2025: $288.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $118.88 | 2024 | Voquezna |
| Corcept Therapeutics | $110.77 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals Lp | $93.42 | 2021-2024 | Farxiga, Airsupra |
| Viiv Healthcare Company | $92.96 | 2025 | |
| Amgen INC. | $53.57 | 2021-2025 | Repatha, Otezla |
| Lilly USA, LLC | $37.02 | 2024 | Mounjaro |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.19 | 2025 | Caplyta |
| Novo Nordisk INC | $29.29 | 2021-2024 | Rybelsus, Ozempic |
| Merck Sharp & Dohme LLC | $27.41 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.59 | 2021 | |
| Exact Sciences Corporation | $15.42 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Greda Cherry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.